A summary of key studies examining the adoption of I4.0 technologies to enhance resilience
| I4.0 implementation (Corpus references) | PSC studies focus | Resilience capabilities building |
|---|---|---|
| Blockchain technology (1,3, 4, 5, 6, 7, 9, 12, 29, 34, 33, 35, 40, 46, 48, 49, 50, 51, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 74, 77, 81, 83, 86, 92, 93, 99, 105, 106, 107, 109, 112 104) | Information flow redesign trusted process interoperability sustainability and effectiveness handling complexity poor-quality pharmaceuticals prevention prevent counterfeit, stolen, or contaminated drugs | Transparency visibility traceability collaboration and coordination flexibility and agility accessibility robustness sustainability supply base optimisation privacy and security |
| Big data analytics Artificial Intelligence Machine learning (4,10, 13, 17, 18, 21, 32, 35, 39, 41, 43, 49, 57, 58, 61, 63, 82, 87, 95, 100, 107, 111) | Organisational performance prediction of disease outbreaks demand forecasts during disruptive events | Sustainability transparency traceability visibility collaboration optimising decision making |
| Internet-of-Things digital twin (DT) (7, 47, 73, 99, 106) | Increase automation information data scarcity | Transparency collaboration and coordination flexibility accessibility |
| Additive manufacturing (AM) technologies (52, 94) | Personalised medical devices or drug delivery systems quality improvement | Flexibility sustainability transparency personalisation |
| Drone (36, 99) | Medicine delivery quality of medicines | Supply base optimisation accessibility |
| I4.0 implementation (Corpus references) | Resilience capabilities building | |
|---|---|---|
| Blockchain technology (1,3, 4, 5, 6, 7, 9, 12, 29, 34, 33, 35, 40, 46, 48, 49, 50, 51, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 74, 77, 81, 83, 86, 92, 93, 99, 105, 106, 107, 109, 112 104) | Information flow redesign trusted process interoperability sustainability and effectiveness handling complexity poor-quality pharmaceuticals prevention prevent counterfeit, stolen, or contaminated drugs | Transparency visibility traceability collaboration and coordination flexibility and agility accessibility robustness sustainability supply base optimisation privacy and security |
| Big data analytics Artificial Intelligence Machine learning (4,10, 13, 17, 18, 21, 32, 35, 39, 41, 43, 49, 57, 58, 61, 63, 82, 87, 95, 100, 107, 111) | Organisational performance prediction of disease outbreaks demand forecasts during disruptive events | Sustainability transparency traceability visibility collaboration optimising decision making |
| Internet-of-Things digital twin ( | Increase automation information data scarcity | Transparency collaboration and coordination flexibility accessibility |
| Additive manufacturing ( | Personalised medical devices or drug delivery systems quality improvement | Flexibility sustainability transparency personalisation |
| Drone (36, 99) | Medicine delivery quality of medicines | Supply base optimisation accessibility |
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.